An observational study in Hypercortisolism and Cushing Syndrome, sponsored by Corcept Therapeutics. Terminated at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2019-07-30.
Sponsored by Corcept Therapeutics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Cushing Syndrome by Corcept Therapeutics — none open to participants now, 1 under way, none of them phase 3. Cushing Syndrome · Corcept Therapeutics.
Among the 16 studies in Cushing Syndrome by Corcept Therapeutics, this one is the only one that started in 2017, is one of 5 observational ones, and was the 9th registered.
123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.
Browse Cushing Syndrome studies →None of the 16 studies in Cushing Syndrome by Corcept Therapeutics is open now. The open studies under Cushing Syndrome, anywhere →
Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: Up to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2017.
This study's enrollment of 2 is below the median of 121 across 63 observational studies indexed under Cushing Syndrome.
Median enrollment 35 across the 11 interventional studies, 24 across the 5 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.
1 of the studies in Cushing Syndrome by Corcept Therapeutics that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Cushing Syndrome by Corcept Therapeutics, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.
This retrospective chart review study seeks to collect data from pediatric patients treated with Korlym (mifepristone) to help provide clinicians with some insight on the potential role of mifepristone in the treatment of pediatric patients with Cushing syndrome.
Only sites that have been identified to have patients appropriate for this protocol will be invited to participate and contribute data on their patients
Data to be collected from a retrospective chart review will include:
Data will be collected for all follow-up visits, up until the most recent encounter prior to IRB approval.
Pediatric patients who have been treated with Korlym for Cushing's syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pediatrics patients with endogenous Cushing syndrome who received at least one dose of Korlym
Drug utilization patterns as assessed by chart review
The retrospective review would analyze the drug utilization patterns of pediatric patients treated with Korlym
Time frame: Length of Korlym therapy, up to 5 years
Weight as assessed by chart review
The retrospective review would analyze changes in Weight (in kg) in pediatric patients treated with Korlym
Time frame: Length of Korlym therapy, up to 5 years
Blood Pressure as assessed by chart review
The retrospective review would analyze changes in Blood Pressure (in mmHg) in pediatric patients treated with Korlym
Time frame: Length of Korlym therapy, up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2017 to primary completion in Feb 2018, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.